HemoSonics, LLC is a privately held medical device company that has developed a point-of-care diagnostic platform designed for blood analysis. The company's platform offers actionable information to guide the management of critical bleeding and clotting, enabling clinicians to choose the right treatment in the right time frame, dramatically improving outcomes. HemoSonics' systems employ a patented approach named sonorheometry (SR), which is faster, easier to use, and has a lower cost than competing technologies. The products combine a flexible test device with targeted disposable test chambers to diagnose specific defects of hemostasis and inform appropriate therapy. Potential clinical applications include trauma, cardiovascular procedures, organ transplantation, orthopedic surgery, neurological surgery, and labor and delivery among others. The technology has undergone clinical and laboratory testing supported by a series of academic and business grants from the National Institutes of Health, the Wallace H. Coulter Foundation for Translational Research, the Office of Naval Research, and private investors.